Is Ocrevus the First-Line Choice for Primary Progressive MS?
Ocrevus (ocrelizumab) is the only FDA-approved disease-modifying therapy specifically for primary progressive multiple sclerosis (PPMS), making it a standard option but not always the outright "preferred" treatment. Guidelines from the American Academy of Neurology (AAN) and National Multiple Sclerosis Society (NMSS) recommend it as the primary DMT for active PPMS—defined by gadolinium-enhancing lesions or significant T2 lesion burden on MRI—due to its demonstrated slowing of disability progression.[1][2] For non-active PPMS, experts often weigh observation or symptom management first, as Ocrevus's benefits are modest (24% risk reduction in confirmed disability progression over 120 weeks in the ORATORIO trial).[3]
How Does Ocrevus Perform in PPMS Clinical Trials?
In the phase 3 ORATORIO trial, Ocrevus reduced the risk of 12-week confirmed disability progression by 24% versus placebo in PPMS patients (hazard ratio 0.76; 95% CI 0.59-0.98; p=0.036). It also cut the annualized relapse rate by 47.8% and slowed brain volume loss.[3] Real-world data from studies like Ocrevus PPMS Experience show similar outcomes, with about 30% of patients stable or improved after 2 years, though many still progress slowly.[4] No head-to-head trials compare it directly to other agents in PPMS.
What Are the Main Alternatives for PPMS Treatment?
No other DMTs are FDA-approved solely for PPMS, but off-label options include:
- Mitoxantrone: Used in aggressive cases; slows progression but carries cardiotoxicity risks (cumulative dose limit 140 mg/m²).[1]
- Rituximab: Similar B-cell mechanism to Ocrevus; some neurologists prefer it for easier access or cost, with comparable efficacy in small PPMS cohorts.[5]
- HSCT (hematopoietic stem cell transplant): High-intensity option for younger patients (<50) with active inflammation; halts progression in 70-80% at 5 years but with serious risks like infection (mortality ~2-5%).[6]
Symptom-focused therapies (e.g., spasticity meds like baclofen, fatigue aids like modafinil) complement any DMT.[2]
| Treatment | PPMS Approval | Key PPMS Benefit | Major Drawbacks |
|-----------|---------------|------------------|-----------------|
| Ocrevus | Yes (2017) | 24% progression reduction | Infusion reactions (40%), infections (60%), progressive multifocal leukoencephalopathy risk |
| Mitoxantrone | No (off-label) | Slows EDSS worsening | Heart failure, leukemia risk |
| HSCT | No (experimental) | Long-term halt (~70%) | High upfront mortality, infertility |
When Do Neurologists Choose Ocrevus Over Other Options?
Ocrevus is prioritized for patients under 55 with recent disability accrual and MRI activity, per AAN guidelines. It's less favored in frail elderly patients due to infection risks or those without radiographic activity, where watchful waiting prevails.[1][7] Cost (~$65,000/year) and IV infusions every 6 months factor in; patient assistance programs cover most insured U.S. cases.[8]
What Side Effects Prompt Patients to Switch?
Common issues include infusion reactions (34-40% in first dose, manageable with pre-meds), upper respiratory infections (50%), and rare PML (1 confirmed PPMS case).[3][9] About 10-15% discontinue due to infections or lack of efficacy; switches often go to rituximab or HSCT trials.[4] Hepatitis B screening is mandatory pre-treatment.
What's Coming for PPMS: Pipeline and Patent Timeline?
Ongoing trials test bispecific antibodies (e.g., tolebrutinib, phase 3 HERCULES trial met endpoint for 31% progression reduction) and remyelination agents like CNM-Au8.[10] Ocrevus patents expire in 2029 (U.S. composition-of-matter), with biosimilars possible by 2031-2032; check DrugPatentWatch.com for updates.[11]
Sources
[1]: AAN 2024 MS Guidelines
[2]: NMSS Treatment Recommendations
[3]: ORATORIO Trial (NEJM 2017)
[4]: Ocrevus Real-World Data (Neurology 2023)
[5]: Rituximab in PPMS Review (Lancet Neurol 2022)
[6]: MIST Trial (Neurology 2019)
[7]: ECTRIMS/EAN 2023 Guidelines
[8]: GoodRx Ocrevus Pricing
[9]: FDA Ocrevus Label
[10]: ClinicalTrials.gov HERCULES
[11]: DrugPatentWatch Ocrevus